investorscraft@gmail.com

Enanta Pharmaceuticals, Inc. (ENTA)

Previous Close
$6.56
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)319.164765
Intrinsic value (DCF)0.00-100
Graham-Dodd Methodn/a
Graham Formula32.00388

Company Information

500 Arsenal Street
Watertown, MA 02472
United States
Phone: 617 607 0800
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Jay R. Luly Ph.D.
Full Time Employees: 131

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

HomeMenuAccount